ISTA Pharmaceuticals, Inc. Announces Conference Call and Webcast of First Quarter 2008 Financial Results

IRVINE, Calif., April 21 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it will release first quarter 2008 financial results on April 30, 2008, after the U.S. markets close. ISTA will host a conference call, with a simultaneous webcast, to discuss these results at 4:30 p.m. Eastern Time on April 30.

To access the live conference call, U.S. and Canadian participants may dial 866-362-5158; international participants may dial 617-597-5397. The access code for the live call is 62850877. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 41268029. This conference call also will be webcast live and archived on ISTA’s website until May 30, 2008, at www.istavision.com.

About ISTA

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA’s products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company’s product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals’ website at http://www.istavision.com.

CONTACT: Vince Anido, +1-949-788-5311, vanido@istavision.com, or Lauren
Silvernail, +1-949-788-5302, lsilvernail@istavision.com, both of ISTA
Pharmaceuticals; or Media, Justin Jackson, jjackson@burnsmc.com, or
Investors, Juliane Snowden, jsnowden@burnsmc.com, or Nicki Kahner,
nkahner@burnsmc.com, all of Burns McClellan, +1-212-213-0006, for ISTA
Pharmaceuticals

Web site: http://www.istavision.com/

MORE ON THIS TOPIC